1. Sulaiman, M.K., Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetology & metabolic syndrome, 2019. 11: p. 7-7.
2. Wang, G., et al., The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases. Journal of Translational Medicine, 2019. 17(1): p. 264.
3. Orchard, T.J., et al., Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes, 1990. 39(9): p. 1116-1124.
4. Otieno, F.C.F., et al., The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening. BMC Nephrology, 2020. 21(1): p. 73.
5. Pedersen, M.L., Diabetes care in the dispersed population of Greenland. A new model based on continued monitoring, analysis and adjustment of initiatives taken. International Journal of Circumpolar Health, 2019. 78(sup1): p. 1709257.
6. Inker, L.A., et al., KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis, 2014. 63(5): p. 713-35.
7. Lim, C.C., et al., Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population. Eur J Prev Cardiol, 2015. 22(8): p. 1018-26.
8. Nichols, G.A., et al., Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrology, 2020. 21(1): p. 167.
9. Xie, Y., et al., Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int, 2018. 94(3): p. 567-581.
10. Pérez-Morales, R.E., et al., Inflammation in Diabetic Kidney Disease. Nephron, 2019. 143(1): p. 12-16.
11. Donate-Correa, J., et al., Inflammatory cytokines in diabetic nephropathy. Journal of diabetes research, 2015. 2015.
12. Soliman, G.Z., Effect of vitamin C and/or vitamin E on kidney, liver and brain functions of streptozotocin-induced diabetic rats. The Egyptian Journal of Hospital Medicine, 2013. 53(1): p. 799-808.
13. Tziomalos, K. and V.G. Athyros, Diabetic nephropathy: new risk factors and improvements in diagnosis. The review of diabetic studies: RDS, 2015. 12(1-2): p. 110.
14. Matoba, K., et al., Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. International journal of molecular sciences, 2019. 20(14): p. 3393.
15. Pasalic, D., N. Marinkovic, and L. Feher-Turkovic, Uric acid as one of the important factors in multifactorial disorders–facts and controversies. Biochemia medica: Biochemia medica, 2012. 22(1): p. 63-75.
16. Schlesinger, N. and L. Brunetti. Beyond urate lowering: analgesic and anti-inflammatory properties of allopurinol. in Seminars in arthritis and rheumatism. 2020. Elsevier.
17. Yiginer, O., et al., Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol, 2008. 97(5): p. 334-40.
18. Lai, S.W., C.L. Lin, and K.F. Liao, Case-control study examining the association between allopurinol use and ischemic cerebrovascular disease. J Investig Med, 2019. 67(1): p. 48-51.
19. Elhefnawy, K.A. and A.M. Elsayed, Prevalence of diabetic kidney disease in patients with type 2 diabetes mellitus. The Egyptian Journal of Internal Medicine, 2019. 31(2): p. 149.
20. Fiseha, T. and Z. Tamir, Prevalence and awareness of chronic kidney disease among adult diabetic outpatients in Northeast Ethiopia. BMC Nephrology, 2020. 21(1): p. 129.
21. Kanbay, M., et al., Allopurinol as a Kidney-Protective, Cardioprotective, and Antihypertensive Agent: Hype or Reality? Blood Purification, 2014. 37(3): p. 172-178.
22. George, J., et al., High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. Circulation, 2007. 114: p. 2508-16.
23. Paisansinsup, T., M.K. Breitenstein, and J.T. Schousboe, Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol. JCR: Journal of Clinical Rheumatology, 2013. 19(4): p. 180-186.
24. Goicoechea, M., et al., Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical Journal of the American Society of Nephrology, 2010. 5(8): p. 1388-1393.
25. Chen, Y.-Y., et al., The association of uric acid with the risk of metabolic syndrome, arterial hypertension or diabetes in young subjects-An observational study. Clinica Chimica Acta, 2018. 478: p. 68-73.
26. Iseki, K., et al., Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res, 2001. 24(6): p. 691-7.
27. Nacak, H., et al., Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant, 2015. 30(12): p. 2039-45.
28. Nacak, H., et al., Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients. BMC Nephrol, 2014. 15: p. 91.
29. Roumeliotis, S., et al., Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review. Nutrients, 2019. 11(8): p. 1911.
30. Goicoechea, M., et al., Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clinical journal of the American Society of Nephrology : CJASN, 2010. 5: p. 1388-93.
31. Sezer, S., et al., Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi Journal of Kidney Diseases and Transplantation, 2014. 25(2): p. 316-320.
32. Gersch, C., et al., Inactivation of nitric oxide by uric acid. Nucleosides, nucleotides & nucleic acids, 2008. 27(8): p. 967-978.